At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Atezolizumab +1 moredrug
Likely dose
Atezolizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Phase II Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Pretreated With Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitors
In Brief
A Phase 2 clinical trial evaluating Atezolizumab and Bevacizumab for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 23 participants across 10 sites.
Detailed Summary
This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC harbored EGFR mutation after EGFR TKI therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartSep 2020
Primary CompletionJan 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedJun 11, 2020
Enrollment StartSep 9, 2020
Primary CompletionJan 19, 2022
Study CompletionFeb 10, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.1 years ago
Interventions
Atezolizumabdrug
Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
Bevacizumabdrug
Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.